Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
The grant seeks to enhance cancer research by using advanced molecular imaging to gain insights into inflammation dynamics in vivo.
Browse similar grants
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Resubmission) | February 5, 2027 (New) | March 5, 2027 (Resubmission) | June 5, 2027 (New) | July 5, 2027 (Resubmission) | October 5, 2027 (New) | November 5, 2027 (Resubmission) | January 7, 2028 (Closing)
Funding Amounts: $500,000 award ceiling; direct-cost budgets below $500,000 annually; up to 5 years
Summary: Supports interdisciplinary R01 research using molecular imaging to understand cancer-associated inflammation in vivo.
Key Information: Multiple principal investigators spanning cancer basic science and imaging science are required; clinical trials are not allowed.
Description
The National Cancer Institute (NCI), part of NIH, supports the development and application of current and emerging molecular imaging methods to investigate cancer-associated inflammation in vivo. The program seeks mechanistic insights into how inflammatory cells and signaling pathways influence tumor behavior, and how these processes change during treatment. Its goals include accelerating tumor-specific therapies and improving monitoring of therapeutic responses.
Projects should integrate cancer biology, immunology, and imaging expertise through substantive team-science collaborations. Supported approaches include targeted imaging probes, reporter genes, quantitative multimodal and multiscale imaging, and adaptation of imaging tools developed for other inflammatory diseases. Combining whole-organism imaging with multi-omics, in vitro, or ex vivo methods is encouraged when it addresses mechanistic hypotheses.
